Compare Amgen, Inc. (AMGN) vs iShares MSCI Malaysia ETF (EWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares MSCI Malaysia ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while iShares MSCI Malaysia ETF trades at $28.07. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares MSCI Malaysia ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | EWM | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $417.20 | $30.42 |
52-Week Low | $271.18 | $24.73 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.
Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →
